GLPwatch
Cagrilintide plus semaglutide for obesity management.
Lancet · 2021
Last updated 2026-08-27| Journal | Lancet, 2021 |
|---|---|
| Citations | 32 |
| Relative citation ratio | 1.98 |
| NIH percentile | 73 |
| Molecules | semaglutide, cagrilintide |
| Conditions studied | Obesity |
Full record and abstract on PubMed 33894837 ↗
Related research
- Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.
- Once-Weekly Semaglutide in Adults with Overweight or Obesity.
- Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes.
- A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis.
- Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes.
- Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.
- Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes.
- Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity.